Is there a vaccine for chicken pox?
Vaccine court
The VICP covers all vaccines listed on the Vaccine Injury Table maintained by the Secretary of Health and Human Services; in 2007 the list included vaccines against diphtheria, tetanus, pertussis (whooping cough), measles, mumps, rubella (German measles), polio, hepatitis B, varicella (chicken pox), "Haemophilus influenzae" type b, rotavirus, and pneumonia. From 1988 until 8 January 2008, 5,263 claims relating to autism, and 2,865 non-autism claims, were made to the VICP. 925 of these claims, one autism-related (see previous rulings), were compensated, with 1,158 non-autism and 350 autism claims dismissed; awards (including attorney's fees) totaled $847 million. The VICP also applies to claims for injuries suffered before 1988; there were 4,264 of these claims of which 1,189 were compensated with awards totaling $903 million.
Globalization and disease
The smallpox vaccine was developed in 1798 by Edward Jenner. By 1979 the disease had been completely eradicated, with no new outbreaks. The WHO stopped providing vaccinations and by 1986, vaccination was no longer necessary to anyone in the world except in the event of future outbreak.
West Nile fever
A vaccine for horses (ATCvet code: ) based on killed viruses exists; some zoos have given this vaccine to their birds, although its effectiveness is unknown. Dogs and cats show few if any signs of infection. There have been no known cases of direct canine-human or feline-human transmission; although these pets can become infected, it is unlikely they are, in turn, capable of infecting native mosquitoes and thus continuing the disease cycle.
AMD3100, which had been proposed as an antiretroviral drug for HIV, has shown promise against West Nile encephalitis. Morpholino antisense oligos conjugated to cell penetrating peptides have been shown to partially protect mice from WNV disease. There have also been attempts to treat infections using ribavirin, intravenous immunoglobulin, or alpha interferon. GenoMed, a U.S. biotech company, has found that blocking angiotensin II can treat the "cytokine storm" of West Nile virus encephalitis as well as other viruses.
Varicella vaccine
Catching "wild" chickenpox as a child has been thought to commonly result in lifelong immunity. Indeed, parents have deliberately ensured this in the past with "pox parties". Historically, exposure of adults to contagious children has boosted their immunity, reducing the risk of shingles. The CDC and corresponding national organisations are carefully observing the failure rate which may be high compared with other modern vaccines—large outbreaks of chickenpox having occurred at schools which required their children to be vaccinated.
Vaccine
The terms "vaccine" and "vaccination" are derived from "Variolae vaccinae" (smallpox of the cow), the term devised by Edward Jenner to denote cowpox. He used it in 1798 in the long title of his "Inquiry into the Variolae vaccinae known as the Cow Pox", in which he described the protective effect of cowpox against smallpox. In 1881, to honor Jenner, Louis Pasteur proposed that the terms should be extended to cover the new protective inoculations then being developed.
Cell culture
Vaccines for polio, measles, mumps, rubella, and chickenpox are currently made in cell cultures. Due to the H5N1 pandemic threat, research into using cell culture for influenza vaccines is being funded by the United States government. Novel ideas in the field include recombinant DNA-based vaccines, such as one made using human adenovirus (a common cold virus) as a vector,
and novel adjuvants.
Vaccinia
Smallpox was the first disease to be widely prevented by vaccination due to pioneering work by the English physician and scientist Edward Jenner, in the eighteenth century, using cowpox virus. Vaccinia virus is the active constituent of the vaccine that eradicated smallpox, making it the first human disease to be eradicated. This endeavour was carried out by the World Health Organization under the Smallpox Eradication Program. Post eradication of smallpox, scientists study vaccinia virus to use as a tool for delivering genes into biological tissues (gene therapy and genetic engineering) and because of concerns about smallpox being used as an agent for bioterrorism.
Paul Offit
In 2002, during a period of fears about bioterrorism, Offit was the only member of the CDC's advisory panel to vote against a program to give smallpox vaccine to tens of thousands of Americans. He later argued on "60 Minutes II" and "The NewsHour with Jim Lehrer" that the risk of harm for people getting the vaccine outweighed the risk of getting smallpox in the U.S. at the time.
Zoonosis
The first vaccine against smallpox by Edward Jenner in 1800 was by infection of a zoonotic bovine virus which caused a disease called cowpox. Jenner had noticed that milkmaids were resistant to smallpox. Milkmaids contracted a milder version of the disease from infected cows that conferred cross immunity to the human disease. Jenner abstracted an infectious preparation of 'cowpox' and subsequently used it to inoculate persons against smallpox. As a result, smallpox has been eradicated globally, and mass vaccination against this disease 
ceased in 1981.
Vanderbilt University
In the 1930s, Ernest William Goodpasture and his colleagues in the School of Medicine invented methods for cultivating viruses and rickettsiae in fertilized chicken eggs. This work made possible the production of vaccines against chicken pox, smallpox, yellow fever, typhus, Rocky mountain spotted fever and other diseases caused by agents that only propagate in living cells. Alfred Blalock, Professor of Surgery, and his assistant Vivian Thomas identified a decrease in blood volume and fluid loss outside the vascular bed as a key factor in traumatic shock and pioneered the use of replacement fluids for its treatment. This treatment saved countless lives in World War II, during which Vanderbilt was one of 131 colleges and universities nationally that took part in the V-12 Navy College Training Program which offered students a path to a Navy commission.
Mozart and smallpox
In 1796, the discovery of vaccination—the use of the related cowpox virus to immunize against smallpox—by Edward Jenner revolutionized the ability of medicine to deal with smallpox. Vaccination reached Vienna around 1800, when yet another local epidemic created impetus for its adoption. One of the doctors trained in the Vienna campaign, named Doutrepout, then brought vaccination to Mozart's native city of Salzburg. According to Halliwell, "popular resistance was fierce," and both the government and the Roman Catholic Church (previously an opponent) took stern measures to promote vaccination. The first relative of Mozart's known to have been vaccinated was Johanna Berchtold von Sonnenberg, called "Jeannette" (1789–1805), Nannerl's youngest child; she was vaccinated during the 1802 campaign in Salzburg.
Smallpox vaccine
The mortality of the severe form of smallpox—"variola major"—was very high without vaccination, up to 35% in some outbreaks. A method of inducing immunity known as inoculation, or "variolation" was practiced before the development of a modern vaccine and likely occurred in Africa and China well before the practice arrived in Europe. It may also have occurred in India, but this is disputed; other investigators contend the ancient Sanskrit medical texts of India do not describe these techniques. The first clear reference to smallpox inoculation was made by the Chinese author Wan Quan (1499–1582) in his "Douzhen xinfa" (痘疹心法) published in 1549. Inoculation for smallpox does not appear to have been widespread in China until the reign era of the Longqing Emperor (r. 1567–1572) during the Ming Dynasty. In China, powdered smallpox scabs were blown up the noses of the healthy. The patients would then develop a mild case of the disease and from then on were immune to it. The technique did have a 0.5–2.0% mortality rate, but that was considerably less than the 20–30% mortality rate of the disease itself. Two reports on the Chinese practice of inoculation were received by the Royal Society in London in 1700; one by Dr. Martin Lister who received a report by an employee of the East India Company stationed in China and another by Clopton Havers. According to Voltaire (1742), the Turks derived their use of inoculation from neighbouring Circassia. Voltaire does not speculate on where the Circassians derived their technique from, though he reports that the Chinese have practiced it "these hundred years".
Louis Odier
On his return to Geneva in 1772, he passed through London and Paris, where he had the opportunity to observe victims of smallpox and the effects of inoculation, also seeing the innovations of the proponents of inoculation and witnessing the criticism they received. In 1769, Dr. Jobst Bose, a Holstein official living in Göttingen, had shown that protection against smallpox can be acquired through ingestion of the milk of sick cows, and in 1774 the Yetminster farmer Benjamin Jesty - personally aware of the lack of susceptibility of cowpox suffers to smallpox - successfully immunised his wife and two sons with a vaccine during a smallpox epidemic, by transferring a small quantity of the pustular matter from cowpox (a less virulent form of the disease) taken from one of his cattle and applying it via a scratch on their arms..
Egg
Many vaccines for infectious diseases are produced in fertile chicken eggs. The basis of this technology was the discovery in 1931 by Alice Miles Woodruff and Ernest William Goodpasture at Vanderbilt University that the rickettsia and viruses that cause a variety of diseases will grow in chicken embryos. This enabled the development of vaccines against influenza, chicken pox, smallpox, yellow fever, typhus, Rocky mountain spotted fever and other diseases.
Smallpox vaccine
Publication of the Inquiry and the subsequent energetic promulgation by Jenner of the idea of vaccination with a virus other than variola virus constituted a watershed in the control of smallpox for which he, more than anyone else deserves the credit.
As vaccination spread, some European countries made it compulsory. Concern about its safety led to opposition and then repeal of legislation in some instances. Compulsory infant vaccination was introduced in England by the 1853 Vaccination Act. By 1871, parents could be fined for non-compliance, and then imprisoned for non-payment. This intensified opposition, and the 1898 Vaccination Act introduced a conscience clause. This allowed exemption on production of a certificate of conscientious objection signed by two magistrates. Such certificates were not always easily obtained and a further Act in 1907 allowed exemption by a statutory declaration which could not be refused. Although theoretically still compulsory, the 1907 Act effectively marked the end of compulsory infant vaccination in England.
History of smallpox
Knowledge of the ability of cowpox to provide immunity from smallpox was present in England before Jenner's discovery. In 1774, a cattle dealer named Benjamin Jesty successfully inoculated his wife and three sons using cowpox. This was before Jenner discovered the immunization capabilities of cowpox. However, Jesty simply performed the procedure; he did not take the discovery any further by inoculating his family with smallpox matter to see if there would be a reaction or perform any other trials. Jenner was the first to prove the effectiveness of vaccination with cowpox using experimentation.
2003 Midwest monkeypox outbreak
In the Midwest outbreak, the CDC issued guidance on the use of smallpox vaccine, Cidofovir, and Vaccinia immune globulin. Twenty-six residents in five states received the smallpox vaccination. This included 24 adults and two children. Among the adults vaccinated were two laboratory workers, before exposure and to 24 persons after exposure (11 health-care workers, seven household contacts, three laboratory workers, two public health veterinarians, and one work contact). One adult who was vaccinated as a child did not have a major vaccine reaction or "take" 7 days after vaccination and required revaccination.
Infectious bovine keratoconjunctivitis
A vaccine, known as "Piliguard", is available in Australia. The vaccine contains three strains of "Morexella bovis" (SAH38, FLA 64, EPP 63) pilli antigen. This stimulates antibody production against the bacterial pilli to prevent their attachment and invasion of the conjunctiva. The company claims the vaccine reduces the incidence and severity of the disease in an individual animal which directly reduces animal suffering and production loss on top of limiting the spread of disease through the herd. This, in turn, reduces the amount of antibioitcs and fly repellent needed during high-risk seasons. The vaccine is marketed in multidose vials and has an adjuvant to create a long-term subcutaneous depot. This means no booster shot is necessary, but severe local reaction can be seen in people who accidentally inoculate themselves. Calves as young as one week old can be treated and no meat, milk, or export slaughter withdrawal is needed.
Capripoxvirus
Animals produce a lifelong immunity to all Capripoxvirus strains if they recover from the viral infection. The Kenyan sheeppox and goatpox vaccines, produced by an intermediate strain, can also be used to generate immunity. The effects of the vaccine are generally long-lasting because Capripoxviruses have a single serotype. Prevention of an outbreak currently require the slaughter of infected and in-contact animals. However, eradication of Capripoxviruses can be achieved through vaccination and strict movement control of animal populations.
Smallpox vaccine
The introduction of the vaccine to the New World took place in Trinity, Newfoundland, in 1798 by Dr. John Clinch, boyhood friend and medical colleague of Jenner. The first smallpox vaccine in the United States was administered in 1799. The physician Valentine Seaman gave his children a smallpox vaccination using a serum acquired from Jenner. By 1800, Jenner's work had been published in all the major European languages and had reached Benjamin Waterhouse in the United States — an indication of rapid spread and deep interest. Despite some concern about the safety of vaccination the mortality using carefully selected vaccine was close to zero, and it was soon in use all over Europe and the United States. 
In 1804 the Balmis Expedition, an official Spanish mission commanded by Francisco Javier de Balmis, sailed to spread the vaccine throughout the Spanish Empire, first to the Canary Islands and on to Spanish Central America. While his deputy, José Salvany, took vaccine to the west and east coasts of Spanish South America, Balmis sailed to Manila in the Philippines and on to Canton and Macao on the Chinese coast. He returned to Spain in 1806.
The question of who first tried cowpox inoculation/vaccination cannot be answered with certainty. Most, but still limited, information is available for Benjamin Jesty, Peter Plett and John Fewster. In 1774 Jesty, a farmer of Yetminster in Dorset, observing that the two milkmaids living with his family were immune to smallpox, inoculated his family with cowpox to protect them from smallpox. He attracted a certain amount of local criticism and ridicule at the time then interest waned. Attention was later drawn to Jesty, and he was brought to London in 1802 by critics jealous of Jenner's prominence at a time when he was applying to Parliament for financial reward. During 1790–92 Peter Plett, a teacher from Holstein, reported limited results of cowpox inoculation to the Medical Faculty of the University of Kiel. However, the Faculty favoured variolation and took no action. John Fewster, a surgeon friend of Jenner's from nearby Thornbury, discussed the possibility of cowpox inoculation at meetings as early as 1765. He may have done some cowpox inoculations in 1796 at about the same time that Jenner vaccinated Phipps. However Fewster, who had a flourishing variolation practice, may have considered this option but used smallpox instead. He thought vaccination offered no advantage over variolation, but maintained friendly contact with Jenner and certainly made no claim of priority for vaccination when critics attacked Jenner's reputation. It seems clear that the idea of using cowpox instead of smallpox for inoculation was considered, and actually tried in the late 18th century, and not just by the medical profession. Therefore, Jenner was not the first to try cowpox inoculation. However, he was the first to publish his evidence and distribute vaccine freely, provide information on selection of suitable material, and maintain it by arm-to-arm transfer. The authors of the official World Health Organization (WHO) account "Smallpox and its Eradication" assessing Jenner's role wrote:
Timeline of vaccines
This is a timeline of the development of prophylactic human vaccines. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became available on the market. Although vaccines exist for the diseases listed below, only smallpox has been eliminated worldwide. The other vaccine-preventable illnesses continue to cause millions of deaths each year. Currently, polio and measles are the targets of active worldwide eradication campaigns.
Chickenpox
In the United States, the Centers for Disease Control and Prevention (CDC) does not require state health departments to report infections of chickenpox, and only 31 states currently volunteer this information. However, in a 2013 study conducted by the social media disease surveillance tool called Sickweather, anecdotal reports of chickenpox infections on Facebook and Twitter were used to measure and rank states with the most infections per capita, with Maryland, Tennessee and Illinois in the top three.
Edward Jenner
Edward Jenner, FRS FRCPE (17 May 1749 – 26 January 1823) was an English physician and scientist who was the pioneer of smallpox vaccine, the world's first vaccine. The terms "vaccine" and "vaccination" are derived from "Variolae vaccinae" (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1796 in the long title of his "Inquiry into the Variolae vaccinae known as the Cow Pox", in which he described the protective effect of cowpox against smallpox.
Chickenpox
Chickenpox is rarely fatal, although it is generally more severe in adult men than in women or children. Non-immune pregnant women and those with a suppressed immune system are at highest risk of serious complications. Arterial ischemic stroke (AIS) associated with chickenpox in the previous year accounts for nearly one third of childhood AIS. The most common late complication of chickenpox is shingles (herpes zoster), caused by reactivation of the "varicella zoster" virus decades after the initial, often childhood, chickenpox infection.
Chickenpox
Because chickenpox is usually more severe in adults than it is in children, some parents deliberately expose their children to the virus, sometimes by taking them to "chickenpox parties". Doctors counter that children are safer getting the vaccine, which is a weakened form of the virus, rather than getting the disease, which can be fatal. Repeated exposure to chickenpox may protect against zoster.
Mumps
The most common preventative measure against mumps is a vaccination with a mumps vaccine, invented by American microbiologist Maurice Hilleman at Merck. The vaccine may be given separately or as part of the MMR immunization vaccine that also protects against measles and rubella. In the US, MMR is now being supplanted by MMRV, which adds protection against chickenpox (varicella, HHV3). The WHO (World Health Organization) recommends the use of mumps vaccines in all countries with well-functioning childhood vaccination programmes. In the United Kingdom it is routinely given to children at age 13 months with a booster at 3–5 years (preschool) This confers lifelong immunity. The American Academy of Pediatrics recommends the routine administration of MMR vaccine at ages 12–15 months and at 4–6 years. In some locations, the vaccine is given again between four and six years of age, or between 11 and 12 years of age if not previously given. The efficacy of the vaccine depends on the strain of the vaccine, but is usually around 80 percent. The Jeryl Lynn strain is most commonly used in developed countries but has been shown to have reduced efficacy in epidemic situations. The Leningrad-Zagreb strain commonly used in developing countries appears to have superior efficacy in epidemic situations.
Chickenpox
Infection in otherwise healthy adults tends to be more severe. Treatment with antiviral drugs (e.g. acyclovir or valacyclovir) is generally advised, as long as it is started within 24–48 hours from rash onset. Remedies to ease the symptoms of chickenpox in adults are basically the same as those used for children. Adults are more often prescribed antiviral medication, as it is effective in reducing the severity of the condition and the likelihood of developing complications. Antiviral medicines do not kill the virus but stop it from multiplying. Adults are advised to increase water intake to reduce dehydration and to relieve headaches. Painkillers such as paracetamol (acetaminophen) are recommended, as they are effective in relieving itching and other symptoms such as fever or pains. Antihistamines relieve itching and may be used in cases where the itching prevents sleep, because they also act as a sedative. As with children, antiviral medication is considered more useful for those adults who are more prone to develop complications. These include pregnant women or people who have a weakened immune system.
John Ring (surgeon)
An attack on cow-pox treatment made by Benjamin Moseley, physician to the Chelsea Hospital, brought from Ring a refutation, Then in August 1799, he met Edward Jenner, and they became friends. From 1799 Ring devoted most of his professional life to the cause of vaccination. He had leading medical men in London sign a document acknowledging that cow-pox was a much milder and safer disease than inoculated smallpox. He went to Ringwood in 1808 at the head of a deputation to investigate some supposed failures of vaccination; feeling was running so high that the deputies carried pistols.
Chickenpox
It is part of the routine immunization schedule in the US. Some European countries include it as part of universal vaccinations in children, but not all countries provide the vaccine due to its cost. In the UK as of 2014, the vaccine is only recommended in people who are particularly vulnerable to chickenpox. This is to keep the virus in circulation thereby exposing the population to the virus at an early age, when it is less harmful, and to reduce the occurrence of shingles in those who have already had chickenpox by repeated exposure to the virus later in life. In populations that have not been immunized or if immunity is questionable, a clinician may order an enzyme immunoassay. An immunoassay measures the levels of antibodies against the virus that give immunity to a person. If the levels of antibodies are low (low titer) or questionable, reimmunization may be done.
Anthrax vaccines
The notion of a weak form of a disease causing immunity to the virulent version was not new; this had been known for a long time for smallpox. Inoculation with smallpox (variolation) was known to result in far less scarring, and greatly reduced mortality, in comparison with the naturally acquired disease. The English physician Edward Jenner (1749–1823) had also discovered (1796) the process of vaccination by using cowpox to give cross-immunity to smallpox and by Pasteur's time this had generally replaced the use of actual smallpox material in inoculation. The difference between smallpox vaccination and anthrax or chicken cholera vaccination was that the weakened form of the latter two disease organisms had been "generated artificially", so a naturally weak form of the disease organism did not need to be found. This discovery revolutionized work in infectious diseases and Pasteur gave these artificially weakened diseases the generic name "vaccines", in honor of Jenner's groundbreaking discovery. In 1885, Pasteur produced his celebrated first vaccine for rabies by growing the virus in rabbits and then weakening it by drying the affected nerve tissue.
Immunity (medical)
In Europe, the induction of active immunity emerged in an attempt to contain smallpox. Immunization, however, had existed in various forms for at least a thousand years. The earliest use of immunization is unknown, however, around 1000 A.D. the Chinese began practicing a form of immunization by drying and inhaling powders derived from the crusts of smallpox lesions. Around the fifteenth century in India, the Ottoman Empire, and east Africa, the practice of inoculation (poking the skin with powdered material derived from smallpox crusts) became quite common. This practice was first introduced into the west in 1721 by Lady Mary Wortley Montagu. In 1798, Edward Jenner introduced the far safer method of deliberate infection with cowpox virus, (smallpox vaccine), which caused a mild infection that also induced immunity to smallpox. By 1800 the procedure was referred to as vaccination. To avoid confusion, smallpox inoculation was increasingly referred to as variolation, and it became common practice to use this term without regard for chronology. The success and general acceptance of Jenner's procedure would later drive the general nature of vaccination developed by Pasteur and others towards the end of the 19th century. In 1891, Pasteur widened the definition of vaccine in honour of Jenner and it then became essential to qualify the term, by referring to polio vaccine, measles vaccine etc.
Canarypox
Canarypox virus (CNPV) is an "Avipoxvirus" and etiologic agent of canarypox, a disease of wild and captive birds that can cause significant losses. Canarypox can enter human cells, but it cannot survive and multiply in human cells. There is a live viral vaccine available which may have beneficial properties against human cancer when used as a mammalian expression vector. (ATCvet code: ). Furthermore, the POXIMUNE® C vaccine does offer direct protection against CNPV in susceptible birds.
MMR vaccine
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses. After two doses 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended in those who do not have evidence of immunity, those with well controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection.
The MMR vaccine is widely used around the world; with over 500 million doses having been given in over 100 countries as of 2001. Measles resulted in 2.6 million deaths per year before immunization became common. This has decreased to 122,000 deaths per year as of 2012, mostly in low income countries. Through vaccination, as of 2018, rates of measles in North and South America are very low. Rates of disease have been seen to increase in populations who go unvaccinated. Between 2000 and 2016, vaccination decreased measles deaths by a further 84%.
Side effects of immunization are generally mild and go away without any specific treatment. These may include fever, and pain or redness at the injection site. Severe allergic reactions occur in about one in a million people. The MMR vaccine is not recommended during pregnancy, however, may be given while breastfeeding. The vaccine is safe to give at the same time as other vaccines. Being recently immunized does not increase the risk of passing measles, mumps, or rubella on to others. Vaccination does not increase the risk of autism. The MMR vaccine is a mixture of live weakened viruses of the three diseases.
The MMR vaccine was developed by Maurice Hilleman. It was licensed for use by Merck in 1971. Stand alone measles, mumps, and rubella vaccines had been previously licensed in 1963, 1967, and 1969 respectively. Recommendations for a second dose were introduced in 1989. The MMRV vaccine which also covers chickenpox may be used instead. An MR vaccine, without coverage for mumps, is also occasionally used.
Zoster vaccine
Zoster vaccines includes a number of vaccines that have been shown to reduce the incidence of herpes zoster (also known as shingles). One type of zoster vaccine is, essentially, a larger-than-normal dose of the chickenpox vaccine, as both shingles and chickenpox are caused by the same virus, the varicella zoster virus (VZV). A recombinant version was approved in the United States in 2017.
Diphtheria vaccine
Diphtheria vaccine is a vaccine against "Corynebacterium diphtheriae", the bacterium that causes diphtheria. Its use has resulted in a more than 90% decrease in number of cases globally between 1980 and 2000. The first dose is recommended at six weeks of age with two additional doses four weeks apart, after which it is about 95% effective during childhood. Three further doses are recommended during childhood. It is unclear if further doses later in life are needed. 
The diphtheria vaccine is very safe. Significant side effects are rare. Pain may occur at the injection site. A bump may form at the site of injection that lasts a few weeks. The vaccine is safe in both pregnancy and among those who have a poor immune function.
The diphtheria vaccine is delivered in several combinations. Some combinations (Td and DT vaccines) include tetanus vaccine, others (known as DPT vaccine or DTaP vaccine depending on the pertussis antigen used) comes with the tetanus and pertussis vaccines, and still others include additional vaccines such as Hib vaccine, hepatitis B vaccine, or inactivated polio vaccine. The World Health Organization has recommended its use since 1974. About 84% of the world population is vaccinated. It is given as a intramuscular injection. The vaccine needs to be kept cold but not frozen.
The diphtheria vaccine was developed in 1923. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale price in the developing world of a version that contains tetanus toxoid is between 0.12 and 0.99 USD per dose as of 2014. In the United States it is less than 25 USD.
Raccoonpox virus
RCN has been developed as a recombinant for the delivery of vaccines against the plague (caused by bacterium "Yersinia pestis"), feline panleukopenia virus, rabies virus and other pathogens in wildlife and domestic animals. Controlling diseases such as the plague in wildlife and domestic animals is important to reducing its transmission to humans.
RCN is favored as a vector for wildlife and veterinary management over other potential poxvirus vectors because it triggers an immune response when it is taken in through mucosal routes, which is important for the widespread immunization of wildlife. Recombinant RCN (rRCN) vaccines been given to a number of mammalian species such as mice, raccoons, cats and sheep without side effects. The rRCN rabies virus glycoprotein recombinant vaccine was effective when given to sheep both intradermally and intramuscularly. Fortunately, the rRCN vaccine did relatively little harm to sheep when ingested orally, suggesting that rRCN vaccines used for wildlife management delivered as oral baits would be safe if accidentally ingested by sheep. Further studies are needed to determine the effect of ingestion of oral bait rRCN vaccines by non-target farm and domestic animals. Particular rRCN vaccines have been designed to effectively confer protective immunity against multiple pathogens. rRCN vaccines have been successful too in treating rabies virus in mice. These vaccines functioned by either expressing the rabies virus internal structural nucleoprotein (RCN-N) or by expressing the rabies virus glycoprotein (RCN-G).
Childhood immunizations in the United States
Most people that get the vaccine will not get chickenpox and in also prevents almost all cases of severe disease that can be a results from the disease. About 25-30% of vaccinated people who get chickenpox can have it as serious as that in an unvaccinated person.
Side effects of this vaccine can include:
More severe symptoms may include
Vaccination policy
To eliminate the risk of disease outbreaks, at various times governments and other institutions established policies requiring vaccination. For example, an 1853 law required universal vaccination against smallpox in England and Wales, with fines levied on people who did not comply. In the United States, the Supreme Court ruled in "Jacobson v. Massachusetts" (1905) that states have the authority to require vaccination against smallpox during a smallpox epidemic. All U.S states require that children be vaccinated in order to attend school; only three states (Mississippi, West Virginia, and California) do not provide exemptions based on religious or philosophical beliefs. A few other countries also follow this practice. Compulsory vaccination greatly reduces infection rates for associated diseases. Beginning in the nineteenth century, these policies stirred resistance from a variety of groups, collectively called anti-vaccinationists, who objected on ethical, political, medical safety, religious, and other grounds. Common objections included government intervention in personal matters or that proposed vaccinations were not sufficiently safe. Many modern vaccination policies allow exemptions for people with compromised immune systems, allergies to vaccination components, or strongly held objections.
Exotoxin
Exotoxins have been used to produce vaccines. This process involves inactivating the toxin, creating a toxoid that does not induce toxin-related illness and is well-tolerated. A widely used toxoid vaccine is the DPT vaccine, which is usually administered in multiple doses throughout childhood with adjuvants and boosters for long-term immunity. DPT vaccine protects against pertussis, tetanus and diphtheria infections, caused by the exotoxin-producing "Bordetella pertussis", "Clostridium tetani" and "Corynebacterium diphtheriae" respectively. Vaccination with the toxoids generates antibodies against the exotoxins, forming immunological memory as protection against subsequent infections. The DPT vaccination may cause adverse side effects, such as swelling, redness and fever, and is contraindicated in some populations. Effective vaccination schedules have reduced rates of mortality linked to pertussis, tetanus and diphtheria but formal controlled trials to test the efficacy of the vaccine have not been conducted. Additionally, pertussis persists endemically and is one of the most common causes of vaccine-preventable deaths.
History of smallpox
In 1799, the physician Valentine Seaman administered the first smallpox vaccine in the United States. He gave his children a smallpox vaccination using a serum acquired from Edward Jenner, the British physician who invented the vaccine from fluid taken from cowpox lesions. Though vaccines were misunderstood and mistrusted at the time, Seaman advocated their use and, in 1802, coordinated a free vaccination program for the poor in New York City.
Rabies vaccine
Rabies vaccine is a vaccine used to prevent rabies. There are a number of vaccines available that are both safe and effective. They can be used to prevent rabies before and for a period of time after exposure to the virus such as by a dog or bat bite. The immunity that develops is long lasting after a full course. Doses are usually given by injection into the skin or muscle. After exposure vaccination is typically used along with rabies immunoglobulin. It is recommended that those who are at high risk of exposure be vaccinated before potential exposure. Vaccines are effective in humans and other animals. Vaccinating dogs is very effective in preventing the spread of rabies to humans.
Rabies vaccines may be safely used in all age groups. About 35 to 45 percent of people develop a brief period of redness and pain at the injection site. About 5 to 15 percent of people may have fever, headaches, or nausea. After exposure to rabies there is no contraindication to its use. Most vaccines do not contain thimerosal. Vaccines made from nerve tissue are used in a few countries, mainly in Asia and Latin America, but are less effective and have greater side effects. Their use is thus not recommended by the World Health Organization.
The first rabies vaccine was introduced in 1885, and was followed by an improved version in 1908. Millions of people globally have been vaccinated and it is estimated that this saves more than 250,000 people a year. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 44 and 78 USD for a course of treatment as of 2014. In the United States a course of rabies vaccine is more than 750 USD.
Varicella vaccine
People who do not develop enough protection when they get the vaccine may develop a mild case of the disease when in close contact with a person with chickenpox. In these cases, people show very little sign of illness. This has been the case of children who get the vaccine in their early childhood and later have contact with children with chickenpox. Some of these children may develop a mild chickenpox also known as breakthrough disease.
Anthrax vaccines
In 1997, the Clinton administration initiated the Anthrax Vaccine Immunization Program (AVIP), under which active U.S. service personnel were to be immunized with the vaccine. Controversy ensued since vaccination was mandatory and GAO published reports that questioned the safety and efficacy of AVA, causing sometimes serious side effects. A Congressional report also questioned the safety and efficacy of the vaccine and challenged the legality of mandatory inoculations. Mandatory vaccinations were halted in 2004 by a formal legal injunction which made numerous substantive challenges regarding the vaccine and its safety. After reviewing extensive scientific evidence, the FDA determined in 2005 that AVA is safe and effective as licensed for the prevention of anthrax, regardless of the route of exposure. In 2006, the Defense Department announced the reinstatement of mandatory anthrax vaccinations for more than 200,000 troops and defense contractors. Despite another lawsuit filed by the same attorneys, the vaccinations are required for most U.S. military units and civilian contractors assigned to homeland bioterrorism defense or deployed in Iraq, Afghanistan or South Korea.
Anthrax vaccine adsorbed
In October 2000, a committee of the Institute of Medicine (IOM) of the National Academy of Sciences was asked by the US Congress to review AVA according to the best available evidence. It issued its study in March 2002. The IOM panel noted that human data on inhalational anthrax prevention is limited due to the natural low incidence of disease and that therefore animal model data are the best we are ever likely to have. Primates and rabbits were considered the best models for human disease. As regards vaccine effectiveness, “The committee finds that the available evidence from studies with humans and animals, coupled with reasonable assumptions of analogy, show that AVA as licensed is an effective vaccine for the protection of humans against anthrax, including inhalational anthrax, caused by all known or plausible engineered strains of "B. anthracis".” With regard to safety, “The committee found no evidence that people face an increased risk of experiencing life-threatening or permanently disabling adverse events immediately after receiving AVA, when compared with the general population. Nor did it find any convincing evidence that people face elevated risk of developing adverse health effects over the longer term, although data are limited in this regard (as they are for all vaccines).” Side effects of AVA were found to be ”comparable to those observed with other vaccines regularly administered to adults”. The committee concluded that AVA is “safe and efficacious” for pre-exposure prevention of inhalational anthrax. It also asserted that a new and improved anthrax vaccine might have greater assurance of consistency than AVA and recommended licensure of a new vaccine requiring fewer doses and producing fewer local reactions.
Typhoid vaccine
Typhoid vaccines are vaccines that prevent typhoid fever. Several types are widely available: typhoid conjugate vaccine (TCV), Ty21a (a live vaccine given by mouth) and Vi capsular polysaccharide vaccine (ViPS) (an injectable subunit vaccine). They are about 30 to 70% effective for the first two years depending on the specific vaccine in question. The Vi-rEPA vaccine has been shown to be efficacious in children.
The World Health Organization (WHO) recommends vaccinating all children in areas where the disease is common. Otherwise they recommend vaccinating those at high risk. Vaccination campaigns can also be used to control outbreaks of disease. Depending on the vaccine, additional doses are recommended every 3 to 7 years. In the United States the vaccine is only recommended in those at high risk such as travellers to areas of the world where the disease is common.
The current vaccines are very safe. Minor side effects may occur at the site of injection. The injectable vaccine is safe in people with HIV/AIDS and the oral vaccine can be used as long as symptoms are not present. While it has not been studied during pregnancy, the non-live vaccines are believed to be safe while the live vaccine is not recommended.
The first typhoid vaccines were developed in 1896 by Almroth Edward Wright, Richard Pfeiffer, and Wilhelm Kolle. Due to side-effects newer formulations are currently recommended. Typhoid vaccines are on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about US$4.44 per dose as of 2014. In the United States they cost $25–50.
1775–82 North American smallpox epidemic
Even today, there is much debate surrounding the use of vaccines. Many parents and caregivers worry about potentially negative side effects associated with the vaccination of infants and children; this is merely and echo of the reaction to the smallpox inoculation and eventual vaccine. At the time of its introduction, almost all were extremely wary of this new medical procedure. It was difficult for colonists to understand how the infection of an otherwise healthy individual could have a positive outcome. However, inoculation saved many lives and protected the Continental Army from possible destruction. The smallpox inoculation program paved the way for the global public health system that is responsible for the control and eradication of many deadly diseases; including but not limited to polio, measles, and diphtheria.
Human uses of animals
Vaccines have been made using animals since their discovery by Edward Jenner in the 18th century. He noted that inoculation with live cowpox afforded protection against the more dangerous smallpox. In the 19th century, Louis Pasteur developed an attenuated (weakened) vaccine for rabies. In the 20th century, vaccines for the viral diseases mumps and polio were developed using animal cells grown in vitro.
Varicella vaccine
The World Health Organization recommends one or two doses with the initial dose given at 12 to 18 months of age. The second dose if given should occur at least one to three months later. This vaccine is a shot given subcutaneously (under the skin). It is recommended for all children under 13 and for everyone 13 or older who has never had chickenpox.
Camelpox
Camelpox outbreaks have a negative effect on the local economies. Outbreaks often lead to the loss of young camels, and render older camels useless in terms of milk and meat production, and transportation. As such, attempts are often made to prevent transmission of the disease. An attenuated vaccine is currently available that provides long term protection against Camelpox if administered when the camel is at least 9 months old. An inactivated vaccine is also available, but must be administered yearly to maintain protection.
Chikungunya
, no approved vaccines are available. A phase-II vaccine trial used a live, attenuated virus, to develop viral resistance in 98% of those tested after 28 days and 85% still showed resistance after one year. However, 8% of people reported transient joint pain, and attenuation was found to be due to only two mutations in the E2 glycoprotein. Alternative vaccine strategies have been developed, and show efficacy in mouse models. In August 2014 researchers at the National Institute of Allergy and Infectious Diseases in the USA were testing an experimental vaccine which uses virus-like particles (VLPs) instead of attenuated virus. All the 25 people participated in this phase 1 trial developed strong immune responses. As of 2015, a phase 2 trial was planned, using 400 adults aged 18 to 60 and to take place at 6 locations in the Caribbean. Even with a vaccine, mosquito population control and bite prevention will be necessary to control chikungunya disease.
Human alphaherpesvirus 3
Within the human body it can be treated by a number of drugs and therapeutic agents including acyclovir for the chicken pox, famciclovir, valaciclovir for the shingles, zoster-immune globulin (ZIG), and vidarabine. VZV immune globulin is also a treatment. Acyclovir is frequently used as the drug of choice in primary VZV infections, and beginning its administration early can significantly shorten the duration of any symptoms. However, reaching an effective serum concentration of acyclovir typically requires intravenous administration, making its use more difficult outside of a hospital.
Anthrax Vaccine Immunization Program
On December 15, 2005, the FDA re-issued a Final Rule & Order on the license status of AVA, clearing the way for mandatory vaccination reinstatement. After reviewing extensive scientific evidence and carefully considering comments from the public, the FDA again determined that the vaccine is licensed for the prevention of anthrax, regardless of the route of exposure. Pertaining to the previous ruling, the DC District Federal Appeals Court declined to vacate or overturn the injunction in 2006, instead mooting the case based on the FDA’s new 2005 licensing of the vaccine.["Doe v. Rumsfeld", 127 Fed. App’x 327 (D.C. Cir. 2006)]
2003 Midwest monkeypox outbreak
No direct antiviral treatment for monkeypox is known, only supportive care and prevention of secondary infection. Use of universal precautions in the care of those with the disease has been shown to prevent human-to-human transmission. However, inoculation with the smallpox vaccine has shown to be effective in abating the progression of the disease in those with active infection, and in the prevention of the disease in the general population.
Avipoxvirus
Vaccines have been developed from strains of the virus for fowlpox, canarypox, pigeonpox, and quailpox to help prevent infection in captive and domestic bird populations. There is no one specific treatment used for birds who have contracted the avipoxvirus. Often the avipoxvirus acts as an immune suppressant, leading to secondary bacterial infections, which are recommended for treatment. Common methods include use of iodine-glycerin applications to assist in healing lesions, use of antibiotics to attempt to control secondary infections, and use of vitamin A to supplement healing of lesions.
Smallpox vaccine
Although Jenner used cowpox, the vaccine now contains a virus immunologically related to cowpox and smallpox viruses called vaccinia which causes a mild infection. The vaccine is infectious, which improves its effectiveness, but causes serious complications for people with impaired immune systems (for example chemotherapy and AIDS patients, and people with eczema), and is not yet considered safe for pregnant women. A woman planning on conceiving within one month should not receive smallpox immunization until after the pregnancy. In the event of an outbreak, the woman should delay pregnancy if possible. Vaccines that only contain attenuated vaccinia viruses (an attenuated virus is one in which the pathogenicity has been decreased through serial passage) have been proposed, but some researchers have questioned the possible effectiveness of such a vaccine. According to the Centers for Disease Control and Prevention (CDC), "vaccination within 3 days of exposure will prevent or significantly lessen the severity of smallpox symptoms in the vast majority of people. Vaccination 4 to 7 days after exposure likely offers some protection from disease or may modify the severity of disease." This, along with vaccinations of so-called first responders, is the current plan of action being devised by the United States Department of Homeland Security (including Federal Emergency Management Agency) in the United States.
Pathogenic Escherichia coli
In 2006, Fort Dodge Animal Health (Wyeth) introduced an effective, live, attenuated vaccine to control airsacculitis and peritonitis in chickens. The vaccine is a genetically modified avirulent vaccine that has demonstrated protection against O78 and untypeable strains.
Smallpox vaccine
Vaccine produced by Copeman's method was the only type issued free to public vaccinators by the English Government Vaccine Establishment from 1899. At the same time the 1898 Vaccination Act banned arm-to-arm vaccination, thus preventing transmission of syphilis by this vaccine. However, private practitioners had to purchase vaccine from commercial producers. Although proper use of glycerine reduced bacterial contamination considerably the crude starting material, scraped from the skin of infected calves, was always heavily contaminated and no vaccine was totally free from bacteria. A survey of vaccines in 1900 found wide variations in bacterial contamination. Vaccine issued by the Government Vaccine Establishment contained 5,000 bacteria per gram, while commercial vaccines contained up to 100,000 per gram. The level of bacterial contamination remained unregulated until the Therapeutic Substances Act, 1925 set an upper limit of 5,000 per gram, and rejected any batch of vaccine found to contain the causative organisms of erysipelas or wound infections. Unfortunately glycerolated vaccine soon lost its potency at ambient temperatures which restricted its use in tropical climates. However, it remained in use into the 1970s where a satisfactory cold chain was available. Animals continued to be widely used by vaccine producers during the smallpox eradication campaign. A WHO survey of 59 producers, some of whom used more than one source of vaccine, found that 39 used calves, 12 used sheep and 6 used water buffalo, whilst only 3 made vaccine in cell culture and 3 in embryonated hens' eggs. English vaccine was occasionally made in sheep during World War I but from 1946 only sheep were used.
Helicobacter pylori
"Helicobacter pylori" is a major cause of certain diseases of the upper gastrointestinal tract. Rising antibiotic resistance increases the need to search for new therapeutic strategies; this might include prevention in the form of vaccination. Much work has been done on developing viable vaccines aimed at providing an alternative strategy to control "H. pylori" infection and related diseases, including stomach cancer. Researchers are studying different adjuvants, antigens, and routes of immunization to ascertain the most appropriate system of immune protection; however, most of the research only recently moved from animal to human trials. An economic evaluation of the use of a potential "H. pylori" vaccine in babies found its introduction could, at least in the Netherlands, prove cost-effective for the prevention of peptic ulcer and stomach cancer. A similar approach has also been studied for the United States.
Anthrax vaccine adsorbed
The vaccine efficacy of AVA in humans was initially established by Philip S. Brachman of the U.S. Public Health Service (PHS) in a controlled study undertaken between 1954 and 1959. The study field sites were four wool-sorting mills in the northeastern United States where employees were sometimes exposed to anthrax spores in the course of their work. Over the five years, 379 vaccinees were compared against 414 unvaccinated control subjects. There were 23 cases among controls (5 of them inhalation anthrax) compared with 3 cases among vaccinated (0 inhalation cases). The vaccine was judged to have a 92.5% vaccine efficacy against all types of anthrax experienced. Subsequently, there were no controlled clinical trials in humans of the efficacy of AVA due to the rarity of the condition (especially in the inhalational form) in humans and the ethical inadmissibility of conducting dangerous challenge studies in human subjects. Supportive animal challenge studies were done, however, showing that unvaccinated animals uniformly die whereas vaccinated animals are protected. About 95% of rhesus monkeys (62 of 65) survived challenge, as did 97% of rabbits (114 of 117). Guinea pigs (which are a poorer model for human anthrax than are monkeys or rabbits) showed a 22% protection (19 of 88).
Chickenpox
The varicella vaccine is recommended in many countries. Some countries require the varicella vaccination or an exemption before entering elementary school. A second dose is recommended five years after the initial immunization. A vaccinated person is likely to have a milder case of chickenpox if they become infected. Immunization within three days following household contact reduces infection rates and severity in children.
Smallpox
The antibodies induced by vaccinia vaccine are cross-protective for other orthopoxviruses, such as monkeypox, cowpox, and variola (smallpox) viruses. Neutralizing antibodies are detectable 10 days after first-time vaccination, and seven days after revaccination. Historically, the vaccine has been effective in preventing smallpox infection in 95 percent of those vaccinated. Smallpox vaccination provides a high level of immunity for three to five years and decreasing immunity thereafter. If a person is vaccinated again later, immunity lasts even longer. Studies of smallpox cases in Europe in the 1950s and 1960s demonstrated that the fatality rate among persons vaccinated less than 10 years before exposure was 1.3 percent; it was 7 percent among those vaccinated 11 to 20 years prior, and 11 percent among those vaccinated 20 or more years prior to infection. By contrast, 52 percent of unvaccinated persons died.
There are side effects and risks associated with the smallpox vaccine. In the past, about 1 out of 1,000 people vaccinated for the first time experienced serious, but non-life-threatening, reactions, including toxic or allergic reaction at the site of the vaccination (erythema multiforme), spread of the vaccinia virus to other parts of the body, and to other individuals. Potentially life-threatening reactions occurred in 14 to 500 people out of every 1 million people vaccinated for the first time. Based on past experience, it is estimated that 1 or 2 people in 1 million (0.000198 percent) who receive the vaccine may die as a result, most often the result of postvaccinial encephalitis or severe necrosis in the area of vaccination (called progressive vaccinia).
Feline infectious peritonitis
There is one intra-nasal FIP vaccine available: its use is controversial but in an independent study the authors concluded that vaccination can protect cats with no or low FCoV antibody titres and that in some cats vaccine failure was probably due to pre-existing infection.There is no substantial evidence that proves that the vaccine created for the prevention of FIP is effective or safe. Studies have been done proving both that the vaccine does and doesn't work. However, due to the different forms of the disease and the fact that it can affect cats differently due to genetics, there is no guarantee that the vaccine will be effective one hundred percent of the time.
Vaccinia
Currently, the vaccine is only administered to health care workers or research personnel who have a high risk of contracting the variola virus, and to the military personnel of the United States of America. Due to the threat of smallpox bioterrorism, there is a possibility the vaccine may have to be widely administered again in the future. Therefore, scientists are currently developing novel vaccine strategies against smallpox which are safer and much faster to deploy during a bioterrorism event.
Anthrax vaccines
Vaccines against the livestock and human disease anthrax—caused by the bacterium "Bacillus anthracis"—have had a prominent place in the history of medicine, from Pasteur’s pioneering 19th-century work with cattle (the first effective bacterial vaccine and the second effective vaccine ever) to the controversial late 20th century use of a modern product to protect American troops against the use of anthrax in biological warfare. Human anthrax vaccines were developed by the Soviet Union in the late 1930s and in the US and UK in the 1950s. The current vaccine approved by the U.S. Food and Drug Administration (FDA) was formulated in the 1960s.
Poliomyelitis eradication
A public health effort to permanently eliminate all cases of poliomyelitis (polio) infection around the world began in 1988, led by the World Health Organization (WHO), the United Nations Children's Fund (UNICEF) and the Rotary Foundation. These organizations, along with the U.S. Centers for Disease Control and Prevention (CDC) and The Gates Foundation, have spearheaded the campaign through the Global Polio Eradication Initiative (GPEI), which helps to coordinate vaccination campaigns, environmental monitoring, evaluation of possible polio cases and logistics. Successful eradication of infectious diseases has been achieved twice before, with smallpox and bovine rinderpest.
Prevention of disease spread is accomplished by vaccination. There are two kinds of polio vaccine—oral polio vaccine (OPV), which uses weakened poliovirus, and inactivated polio vaccine (IPV), which is injected. The OPV is less expensive and easier to administer, and can spread immunity beyond the person vaccinated, creating contact immunity. It has been the predominant vaccine used. However, under conditions of long-term vaccine virus circulation in under-vaccinated populations, mutations can reactivate the virus to produce a polio-inducing strain, while the OPV can also, in rare circumstances, induce polio or persistent asymptomatic infection in vaccinated individuals, particularly those that are immunodeficient. Being inactivated, the IPV is free of these risks but does not induce contact immunity. IPV is more costly and the logistics of delivery are more challenging.
The 22 diagnosed wild polio virus (WPV) cases worldwide in 2017 represented a reduction from the 719 diagnosed cases in 2000 and a reduction from the estimated 350,000 cases when the eradication effort began in 1988. Of the three strains of polio virus, the last recorded wild case caused by type 2 (WPV2) was in 1999, and WPV2 was declared eradicated in 2015. Type 3 (WPV3) is last known to have caused polio on 11 November 2012, with all wild-virus cases since that date being due to type 1 (WPV1). All three types are represented among the periodic cases arising from mutated oral vaccine strains, so-called circulating vaccine-derived poliovirus (cVDPV). India is the latest country to have officially stopped endemic transmission of polio, with its last reported case in 2011. Three countries remain where the disease is endemic—Afghanistan, Pakistan and Nigeria.
Immunization
Before the introduction of vaccines, people could only become immune to an infectious disease by contracting the disease and surviving it. Smallpox (variola) was prevented in this way by inoculation, which produced a milder effect than the natural disease. The first clear reference to smallpox inoculation was made by the Chinese author Wan Quan (1499–1582) in his "Douzhen xinfa" (痘疹心法) published in 1549. In China, powdered smallpox scabs were blown up the noses of the healthy. The patients would then develop a mild case of the disease and from then on were immune to it. The technique did have a 0.5–2.0% mortality rate, but that was considerably less than the 20–30% mortality rate of the disease itself. Two reports on the Chinese practice of inoculation were received by the Royal Society in London in 1700; one by Dr. Martin Lister who received a report by an employee of the East India Company stationed in China and another by Clopton Havers. According to Voltaire (1742), the Turks derived their use of inoculation from neighbouring Circassia. Voltaire does not speculate on where the Circassians derived their technique from, though he reports that the Chinese have practiced it "these hundred years".It was introduced into England from Turkey by Lady Mary Wortley Montagu in 1721 and used by Zabdiel Boylston in Boston the same year. In 1798 Edward Jenner introduced inoculation with cowpox (smallpox vaccine), a much safer procedure. This procedure, referred to as vaccination, gradually replaced smallpox inoculation, now called variolation to distinguish it from vaccination. Until the 1880s vaccine/vaccination referred only to smallpox, but Louis Pasteur developed immunization methods for chicken cholera and anthrax in animals and for human rabies, and suggested that the terms vaccine/vaccination should be extended to cover the new procedures. This can cause confusion if care is not taken to specify which vaccine is used e.g. measles vaccine or influenza vaccine.
Smallpox
The first hemisphere-wide effort to eradicate smallpox was made in 1950 by the Pan American Health Organization. The campaign was successful in eliminating smallpox from all American countries except Argentina, Brazil, Colombia, and Ecuador. In 1958 Professor Viktor Zhdanov, Deputy Minister of Health for the USSR, called on the World Health Assembly to undertake a global initiative to eradicate smallpox. The proposal (Resolution WHA11.54) was accepted in 1959. At this point, 2 million people were dying from smallpox every year. Overall, the progress towards eradication was disappointing, especially in Africa and in the Indian subcontinent. In 1966 an international team, the Smallpox Eradication Unit, was formed under the leadership of an American, Donald Henderson. In 1967, the World Health Organization intensified the global smallpox eradication by contributing $2.4 million annually to the effort, and adopted the new disease surveillance method promoted by Czech epidemiologist Karel Raška.
In the early 1950s an estimated 50 million cases of smallpox occurred in the world each year. To eradicate smallpox, each outbreak had to be stopped from spreading, by isolation of cases and vaccination of everyone who lived close by. This process is known as "ring vaccination". The key to this strategy was the monitoring of cases in a community (known as surveillance) and containment. The initial problem the WHO team faced was inadequate reporting of smallpox cases, as many cases did not come to the attention of the authorities. The fact that humans are the only reservoir for smallpox infection, and that carriers did not exist, played a significant role in the eradication of smallpox. The WHO established a network of consultants who assisted countries in setting up surveillance and containment activities. Early on, donations of vaccine were provided primarily by the Soviet Union and the United States, but by 1973, more than 80 percent of all vaccine was produced in developing countries.
Dermatophytosis
no approved human vaccine exist against "Dermatophytosis". For horses, dogs and cats there is available an approved inactivated vaccine called "Insol Dermatophyton" (Boehringer Ingelheim) which provides time-limited protection against several trichophyton and microsporum fungal strains. With cattle, systemic vaccination has achieved effective control of ringworm. Since 1979 a Russian live vaccine (LFT 130) and later on a Czechoslovakian live vaccine against bovine ringworm has been used. In Scandinavian countries vaccination programmes against ringworm are used as a preventive measure to improve the hide quality. In Russia, fur-bearing animals (silver fox, foxes, polar foxes) and rabbits have also been treated with vaccines.
Measles vaccine
Measles vaccine is a vaccine that prevents measles. After one dose at the age of nine months 85% are immune, while a dose at twelve months results in 95% immunity to measles. Nearly all of those who do not develop immunity after a single dose develop it after a second dose. When rates of vaccination within a population are greater than ~92% outbreaks of measles typically no longer occur; however, they may occur again if rates of vaccination decrease. The vaccine's effectiveness lasts many years. It is unclear if it becomes less effective over time. The vaccine may also protect against measles if given within a couple of days after exposure to measles.
The vaccine is generally safe, even for those with HIV infections. Side effects are usually mild and short lived. These may include pain at the site of injection or mild fever. Anaphylaxis has been documented in about 3.5–10 cases per million doses. Rates of Guillain–Barré syndrome, autism and inflammatory bowel disease do not appear to be increased by measles vaccination.
The vaccine is available both by itself and in combinations such as the MMR vaccine (a combination with the rubella vaccine and mumps vaccine) or the MMRV vaccine (a combination of MMR with the chickenpox vaccine). The measles vaccine is equally effective for preventing measles in all formulations, but side effects vary depending with the combination. The World Health Organization recommends measles vaccine be given at nine months of age in areas of the world where the disease is common, or at twelve months where the disease is not common. Measles vaccine is based on a live but weakened strain of measles. It comes as a dried powder which is mixed with a specific liquid before being injected either just under the skin or into a muscle. Verification that the vaccine was effective can be determined by blood tests.
About 85% of children globally have received this vaccine as of 2013. In 2015, at least 160 countries provided two doses in their routine immunization. It was first introduced in 1963. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 0.70 USD per dose as of 2014.
Targeted immunization strategies
The success of vaccines and anti-virus software in preventing major outbreaks relies on the mechanism of herd immunity, also known as community immunity, where the immunization of individuals provides protection for not only the individuals, but also the community at large. In cases of biological contagions such as influenza, measles, and chicken pox, immunizing a critical community size can provide protection against the disease for members who cannot be vaccinated themselves (infants, pregnant women, and immunocompromised individuals). Often however these vaccine programmes require the immunization of a large majority of the population to provide herd immunity. A few successful vaccine programmes have led to the eradication of infectious diseases like small pox and rinderpest, and the near eradication of polio, which plagued the world before the second half of the 20th century.
Bette Korber
In collaboration with Dr. Dan Barouch, a professor at Harvard Medical School, some of these antigens have been tested in monkeys as possible vaccines.  With one series of tests, Barouch checked a number of possible ways to deliver the virus genes and chose to use the common cold virus as a vehicle. The tested mosaic vaccine routinely slowed monkey infection with the closely related Simian Immunodeficiency Virus (SIV), and for 66 percent of monkeys exposed multiple times, no infection resulted. Next, in collaboration with the National Institutes of Health, Janssen Pharmaceutical Companies (a division of Johnson & Johnson), and the Bill and Melinda Gates Foundation, the researchers tested a mosaic vaccine for safety in human subjects; it passed that test too. In 2017, the group of collaborators announced a human efficiency test with that same mosaic protein preparation, vaccinating 2,600 women in Sub Saharan Africa, who will be examined for several years to show how efficiently, if at all, the virus interferes with infection. Korber cautioned that effectiveness of this strategy in monkeys is not a guarantee that a human vaccine will work.
Pandemrix
Pandemrix is an influenza vaccine for influenza pandemics, such as the H1N1 2009 flu pandemic colloquially called the swine flu. The vaccine was developed by GlaxoSmithKline and patented in September 2006.
Influenza vaccine
, both the conventional injection and the nasal spray are manufactured using chicken eggs. The European Union has also approved Optaflu, a vaccine produced by Novartis using vats of animal cells. This technique is expected to be more scalable and avoid problems with eggs, such as allergic reactions and incompatibility with strains that affect avians like chickens.
Research continues into the idea of a "universal" influenza vaccine that would not require tailoring to a particular strain, but would be effective against a broad variety of influenza viruses. However, no vaccine candidates had been announced by Nov 2007.
Donald Henderson
The USAID initiative provided an important impetus to a World Health Organization (WHO) program to eradicate smallpox throughout the world within a 10-year period. In 1966, Henderson moved to Geneva to become director of the campaign. At that time, smallpox was occurring widely throughout Brazil and in 30 countries in Africa and South Asia. More than 10 million cases and 2 million deaths were occurring annually. Vaccination brought some control, but the key strategy was "surveillance-containment". This technique entailed rapid reporting of cases from all health units and prompt vaccination of household members and close contacts of confirmed cases. WHO staff and advisors from some 73 countries worked closely with national staff. The last case occurred in Somalia on October 26, 1977, only 10 years after the program began. Three years later, the World Health Assembly recommended that smallpox vaccination could cease. Smallpox is the first human disease ever to be eradicated. This success gave impetus to WHO’s global Expanded Program on Immunization, which targeted other vaccine-preventable diseases, including poliomyelitis, measles, tetanus, diphtheria, and whooping cough. Now targeted for eradication are poliomyelitis and Guinea Worm disease; after 25 years, this objective is close to being achieved.
Cowpox
The majority of the population at the time accepted the up-and-coming vaccination. However, there were still opposition from individuals who were reluctant to change from the inoculations. In addition, there became a growing concern from parties who were worried about the unknown repercussions of infecting a human with an animal disease. One way individuals expressed their discontent was to draw comics that sometimes depicted small cows growing from the sites of vaccination. Others publicly advocated for the continuance of the inoculations; however this was not because of their discontent for the vaccinations. Some of their reluctance had to do with an apprehensiveness for change. They had become so familiar with the process, outcome, positives, and negatives of inoculations that they did not want to be surprised by the outcome or effects of the vaccinations. Jenner soon eased their minds after extensive trials. However, others advocated against vaccinations for different reason. Because of the high price of inoculation, Jenner experienced very few common folk who were not willing to accept the vaccination. Due to this, Jenner found many subjects for his tests. He was able to publish his results in a pamphlet in 1798: "An Inquiry into the Causes and Effects of Variolae Vaccinae, a Disease, Discovered in some of the Western Counties of England particularly Gloucestershire, and known by the Name of Cow Pox."
Smallpox vaccine
In the late 1940s and early 1950s, Leslie Collier, an English microbiologist working at the Lister Institute of Preventive Medicine, developed a method for producing a heat-stable freeze-dried vaccine in powdered form. Collier added 0.5% phenol to the vaccine to reduce the number of bacterial contaminants but the key stage was to add 5% peptone to the liquid vaccine before it was dispensed into ampoules. This protected the virus during the freeze drying process. After drying the ampoules were sealed under nitrogen. Like other vaccines, once reconstituted it became ineffective after 1–2 days at ambient temperatures. However, the dried vaccine was 100% effective when reconstituted after 6 months storage at allowing it to be transported to, and stored in, remote tropical areas. Collier's method was increasingly used and, with minor modifications, became the standard for vaccine production adopted by the WHO Smallpox Eradication Unit when it initiated its global smallpox eradication campaign in 1967, at which time 23 of 59 manufacturers were using the Lister strain.
Smallpox
Smallpox was an infectious disease caused by one of two virus variants, "variola major" and "variola minor". The last naturally occurring case was diagnosed in October 1977 and the World Health Organization (WHO) certified the global eradication of the disease in 1980. The risk of death following contracting the disease was about 30%, with higher rates among babies. Often those who survived had extensive scarring of their skin and some were left blind.
The initial symptoms of the disease included fever and vomiting. This was followed by formation of sores in the mouth and a skin rash. Over a number of days the skin rash turned into characteristic fluid filled bumps with a dent in the center. The bumps then scabbed over and fell off leaving scars. The disease used to spread between people or via contaminated objects. Prevention was by the smallpox vaccine. Once the disease had developed certain antiviral medication may have helped.
The origin of smallpox is unknown. The earliest evidence of the disease dates back to the 3rd century BCE in Egyptian mummies. The disease historically occurred in outbreaks. In 18th-century Europe it is estimated 400,000 people per year died from the disease, and one-third of the cases resulted in blindness. These deaths included those of four reigning monarchs and a queen consort. In the 20th century it is estimated that smallpox resulted in 300–500 million deaths. As recently as 1967, 15 million cases occurred a year.
Edward Jenner discovered in 1798 that vaccination could prevent smallpox. In 1967, the WHO intensified efforts to eliminate the disease. Smallpox is one of two infectious diseases to have been eradicated, the other being rinderpest in 2011. The term "smallpox" was first used in Britain in the 15th century to distinguish the disease from syphilis, which was then known as the "great pox". Other historical names for the disease include pox, speckled monster, and red plague.
Chickenpox
The duration of the visible blistering caused by varicella zoster virus varies in children usually from 4 to 7 days, and the appearance of new blisters begins to subside after the fifth day. Chickenpox infection is milder in young children, and symptomatic treatment, with sodium bicarbonate baths or antihistamine medication may ease itching. Paracetamol (acetaminophen) is widely used to reduce fever. Aspirin, or products containing aspirin, should not be given to children with chickenpox, as it can cause Reye's Syndrome.
Smallpox vaccine
Jenner sent a paper reporting his observations to the Royal Society in April 1797. Its contents are unknown. It was not submitted formally and there is no mention of it in the Society's records. Jenner had sent the paper informally to Sir Joseph Banks, the Society's president, who asked Everard Home for his views. His report, published for the first time in 1999, was sceptical and called for further vaccinations. These were done and in 1798 Jenner published an analysis of 23 'cases' including several individuals who had resisted natural exposure after previous cowpox. It is not known how many Jenner vaccinated or challenged by inoculation with smallpox virus; e.g. Case 21 included 'several children and adults'. Crucially all of at least four who Jenner deliberately inoculated with smallpox virus resisted it. These included the first and last patients in a series of arm-to-arm transfers. He concluded that cowpox inoculation was a safe alternative to smallpox inoculation, but rashly claimed that the protective effect was lifelong. This last proved to be incorrect. Jenner also tried to distinguish between 'True' cowpox which produced the desired result and 'Spurious' cowpox which was ineffective and/or produced severe reaction. Modern research suggests Jenner was trying to distinguish between effects caused by what would now be recognised as noninfectious vaccine, a different virus (e.g. paravaccinia/milker's nodes), or contaminating bacterial pathogens. This caused confusion at the time, but would become important criteria in vaccine development. A further source of confusion was Jenner's belief that fully effective vaccine obtained from cows originated in an equine disease, which he mistakenly referred to as "grease". This was criticised at the time but vaccines derived from horsepox were soon introduced and later contributed to the complicated problem of the origin of vaccinia virus, the virus in present-day vaccine.
Vaccine controversies
Scientific evidence for the effectiveness of large-scale vaccination campaigns is well established. Vaccination campaigns helped eradicate smallpox, which once killed as many as one in seven children in Europe, and have nearly eradicated polio. As a more modest example, infections caused by "Haemophilus influenzae", a major cause of bacterial meningitis and other serious diseases in children, have decreased by over 99% in the US since the introduction of a vaccine in 1988. It is estimated that full vaccination, from birth to adolescence, of all US children born in a given year would save 33,000 lives and prevent 14 million infections.
Varicella vaccine
Approximately 5% of children who receive the vaccine develop a fever or rash. Adverse reaction reports for the period 1995 to 2005 found no deaths attributed to the vaccine despite approximately 55.7 million doses being delivered.
Cases of vaccine-related chickenpox have been reported in patients with a weakened immune system, but no deaths.
Varicella vaccine
Regarding herpes zoster, the US Centers for Disease Control states: "Chickenpox vaccines contain weakened live VZV, which may cause latent (dormant) infection. The vaccine-strain VZV can reactivate later in life and cause shingles. However, the risk of getting shingles from vaccine-strain VZV after chickenpox vaccination is much lower than getting shingles after natural infection with wild-type VZV."
Smallpox vaccine
Perhaps there was already an informal public understanding of some connection between disease resistance and working with cattle. The "beautiful milkmaid" seems to have been a frequent image in the art and literature of this period. But it is known for certain that in the years following 1770, at least six people in England and Germany (Sevel, Jensen, Jesty 1774, Rendall, Plett 1791) tested successfully the possibility of using the cowpox vaccine as an immunization for smallpox in humans. In 1796, Sarah Nelmes, a local milkmaid, contracted cowpox and went to Jenner for treatment. Jenner took the opportunity to test his theory. He inoculated James Phipps, the eight-year-old son of his gardener, with material taken from the cowpox lesions on Sarah's hand. After a mild fever and the expected local lesion James recovered after a few days. About two months later Jenner inoculated James on both arms with material from a case of smallpox, with no effect; the boy was immune to smallpox.
Seth Lederman
TNX-801 is a new potential vaccine for smallpox. TNX-801 is a synthetic form of horsepox, which is an otherwise extinct virus. Evolutionary analysis of modern vaccines indicates that the vaccine isolated and used by Edward Jenner to vaccinate against smallpox was either horsepox or something quite similar. A 1902 sample of vaccinia smallpox vaccine was characterized and found to be 99.7% similar to horsepox, further supporting the connection with Jenner's vaccine. The synthesis of horsepox was a collaboration with David Evans and Ryan Noyce at the University of Alberta in Edmonton, Alberta, Canada. TNX-801 or horsepox is the first poxvirus, or poxviridae, to be synthesized and provides a platform for developing new vaccines against infectious disease and cancer. The finding that a horsepox vaccine was in clinical use in the U.S. in 1902 to protect against smallpox provides strong support for the efficacy of TNX-801 horsepox vaccine to protect against smallpox.
West African Ebola virus epidemic
In July 2015, researchers announced that a vaccine trial in Guinea had been completed that appeared to give protection from the virus. The vaccine, rVSV-ZEBOV, had shown 100% efficacy in individuals, but more conclusive evidence was needed regarding its capacity to protect populations through "herd immunity" . The vaccine trial employed "ring vaccination", a technique that was also used in the 1970s to eradicate smallpox, in which health workers control an outbreak by vaccinating all suspected infected individuals within the surrounding area.
1947 New York City smallpox outbreak
On April 4, 1947, New York City Mayor William O'Dwyer and Commissioner of Health Israel Weinstein informed the public about the smallpox outbreak and announced plans to vaccinate everybody in the city. At the time, the New York City Health Department had 250,000 individual doses of vaccine and 400,000 doses in bulk. O'Dwyer called an emergency meeting with the heads of the seven American pharmaceutical companies involved in vaccine production and asked them for a commitment to provide 6 million doses of vaccine. The pharmaceutical companies accomplished the task by putting the vaccine into round-the-clock production. Additional vaccine doses were obtained from the Army and Navy.
Thymidine kinase
After smallpox was declared eradicated by WHO in December 1979, vaccination programs were terminated. A re-emergence of the disease either by accident or as a result of biological warfare would meet an unprotected population and could result in an epidemic that could be difficult to control. Mass vaccination would be unethical, as the only efficient vaccines against smallpox include live vaccinia virus with severe adverse effects on rare occasions. As one protective measure, large amounts of vaccine are kept in stock, but an efficient drug against smallpox has high priority. One possible approach would be to use the specificity of the thymidine kinase of poxvirus for the purpose, in a similar way that it is used for drugs against herpesvirus. One difficulty is that the poxvirus thymidine kinase belongs to the same family of thymidine kinases as the human thymidine kinases and thereby is more similar chemically. The structure of poxvirus thymidine kinases has therefore been determined to find potential antiviral drugs. The search has, however, not yet resulted in a usable antiviral drug against poxviruses.
Koch–Pasteur rivalry
Rabies, uncommon but excruciating and almost invariably fatal, was dreaded. Amid anthrax vaccine's success, Pasteur introduced rabies vaccine (1885), the first human vaccine since Jenner's smallpox vaccine (1796). On 6 July 1885, the vaccine was tested on 9-year old Joseph Meister who had been bitten by a rabid dog but failed to develop rabies, and Pasteur was called a hero. (Even without vaccination, not everyone bitten by a rabid dog develops rabies.) After other apparently successful cases, donations poured in from across the globe, funding the establishment of the Pasteur Institute, the globe's first biomedical institute, which opened in Paris in 1888.
Vaccine
Besides recommendations for infant vaccinations and boosters, many specific vaccines are recommended for other ages or for repeated injections throughout life—most commonly for measles, tetanus, influenza, and pneumonia. Pregnant women are often screened for continued resistance to rubella. The human papillomavirus vaccine is recommended in the U.S. (as of 2011) and UK (as of 2009). Vaccine recommendations for the elderly concentrate on pneumonia and influenza, which are more deadly to that group. In 2006, a vaccine was introduced against shingles, a disease caused by the chickenpox virus, which usually affects the elderly.
Smallpox
The English physician Edward Jenner demonstrated the effectiveness of cowpox to protect humans from smallpox in 1796, after which various attempts were made to eliminate smallpox on a regional scale. In Russia in 1796, the first child to receive this treatment was bestowed the name "Vaccinov" by Catherine the Great, and was educated at the expense of the nation. The introduction of the vaccine to the New World took place in Trinity, Newfoundland in 1800 by Dr. John Clinch, boyhood friend and medical colleague of Jenner. As early as 1803, the Spanish Crown organized the Balmis expedition to transport the vaccine to the Spanish colonies in the Americas and the Philippines, and establish mass vaccination programs there. The U.S. Congress passed the Vaccine Act of 1813 to ensure that safe smallpox vaccine would be available to the American public. By about 1817, a very solid state vaccination program existed in the Dutch East Indies. In British India a program was launched to propagate smallpox vaccination, through Indian vaccinators, under the supervision of European officials. Nevertheless, British vaccination efforts in India, and in Burma in particular, were hampered by stubborn indigenous preference for inoculation and distrust of vaccination, despite tough legislation, improvements in the local efficacy of the vaccine and vaccine preservative, and education efforts. By 1832, the federal government of the United States established a smallpox vaccination program for Native Americans. In 1842, the United Kingdom banned inoculation, later progressing to mandatory vaccination. The British government introduced compulsory smallpox vaccination by an Act of Parliament in 1853. In the United States, from 1843 to 1855 first Massachusetts, and then other states required smallpox vaccination. Although some disliked these measures, coordinated efforts against smallpox went on, and the disease continued to diminish in the wealthy countries. In Northern Europe a number of countries had eliminated smallpox by 1900, and by 1914, the incidence in most industrialized countries had decreased to comparatively low levels. Vaccination continued in industrialized countries, until the mid to late 1970s as protection against reintroduction. Australia and New Zealand are two notable exceptions; neither experienced endemic smallpox and never vaccinated widely, relying instead on protection by distance and strict quarantines.
Lyme disease microbiology
A vaccine based on the surface protein OspA (LYMErix; SmithKline Beecham) was licensed for use in adults. However, the manufacturer voluntarily removed the vaccine from the market in 2002. The current focus is on vaccine candidates that require fewer boosts and provide long-term protection. Interest is developing in vaccines that specifically target the tick vectors of Lyme disease, specifically components of tick saliva that coat the bacteria. This approach offers the advantage of protecting against multiple pathogens with one vaccine. While an effective Lyme disease vaccine seems likely to be developed, earlier experiences with the LYMErix vaccine suggest bringing such a vaccine to market will be a challenge.
Lyme disease
Vaccines have been formulated and approved for prevention of Lyme disease in dogs. Currently, three Lyme disease vaccines are available. LymeVax, formulated by Fort Dodge Laboratories, contains intact dead spirochetes which expose the host to the organism. Galaxy Lyme, Intervet-Schering-Plough's vaccine, targets proteins OspC and OspA. The OspC antibodies kill any of the bacteria that have not been killed by the OspA antibodies. Canine Recombinant Lyme, formulated by Merial, generates antibodies against the OspA protein so a tick feeding on a vaccinated dog draws in blood full of anti-OspA antibodies, which kill the spirochetes in the tick's gut before they are transmitted to the dog.
Mumps vaccine
Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between the age of 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful.
Side effects are generally mild. It may cause mild pain and swelling at the site of injection and mild fever. More significant side effects are rare. Evidence is insufficient to link the vaccine to complications such as neurological effects. The vaccine should not be given to people who are pregnant or have very poor immune system function. Poor outcomes among children of mothers who received the vaccine during pregnancy, however, have not been documented. Even though the vaccine is developed in chicken cells, it is generally safe to give to those with egg allergies.
Most of the developed world and many countries in the developing world include it in their immunization programs often in combination with measles and rubella vaccine known as MMR. A formulation with the previous three and the varicella vaccine known as MMRV is also available. As of 2005 110 countries provided the vaccine as part of their immunization programs. In areas where widespread vaccination is carried out it has resulted in a more than 90% decline in rates of disease. Almost half a billion doses of one variety of the vaccine has been given.
A mumps vaccine was first licensed in 1948; however it only had short term effectiveness. Improved vaccines became commercially available in the 1960s. While the initial vaccine was Inactivated subsequent preparations are live virus that has been weakened. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. There are a number of different types in use as of 2007. The wholesale cost in the developing world of the version that includes measles and rubella is 0.24 USD per dose as of 2014.
The vaccine is a component of Merck's three-virus MMR vaccine. Mumpsvax is given by a subcutaneous injection of live virus reconstituted from freeze-dried (lyophilized) vaccine.
Pertussis vaccine
Pertussis vaccine is a vaccine that protects against whooping cough (pertussis). There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. The effectiveness of the vaccines appears to decrease by between 2 and 10% per year after vaccination with a more rapid decrease with the acellular vaccines. Vaccinating the mother during pregnancy may protect the baby. The vaccine is estimated to have saved over 500,000 lives in 2002.
The World Health Organization and Center for Disease Control and Prevention recommend all children be vaccinated for pertussis and that it be included in routine vaccinations. This includes for people who have HIV/AIDS. Three doses starting at six weeks of age are typically recommended in young children. Additional doses may be given to older children and adults. The vaccine is only available in combination with tetanus and diphtheria vaccines.
The acellular vaccines are more commonly used in the developed world due to fewer adverse effects. Between 10 and 50% of people given the whole-cell vaccines develop redness at the injection site or fever. Febrile seizures and long periods of crying occur in less than 1% of people. With the acellular vaccines a brief period of non-serious swelling of the arm may occur. Side effects with both types of vaccines, but especially the whole-cell vaccine, are less common the younger the child. The whole-cell vaccines should not be used after seven years of age. Serious long term neurological problems are not associated with either type.
The pertussis vaccine was developed in 1926. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. A version that also includes tetanus, diphtheria, polio, and Hib vaccine is available wholesale in the developing world at a cost of 15.41 USD per dose as of 2014.
Varicella vaccine
Some vaccinated children have been found to lose their protective antibody in as little as five to eight years. However, according to the World Health Organization: "After observation of study populations for periods of up to 20 years in Japan and 10 years in the United States, more than 90% of immunocompetent persons who were vaccinated as children were still protected from varicella." However, since only one out of five Japanese children were vaccinated, the annual exposure of these vaccinees to children with natural chickenpox boosted the vaccinees' immune system. In the United States, where universal varicella vaccination has been practiced, the majority of children no longer receive exogenous (outside) boosting, thus, their cell-mediated immunity to VZV (varicella zoster virus) wanes—necessitating booster chickenpox vaccinations. As time goes on, boosters may be necessary. Persons exposed to the virus after vaccine tend to experience milder cases of chickenpox.
Monkeypox
Monkeypox is an infectious disease caused by the monkeypox virus that can occur in certain animals including humans. Symptoms begin with fever, headache, muscle pains, swollen lymph nodes, and feeling tired. This is followed by a rash that forms blisters and crusts over. The time from exposure to onset of symptoms is around 10 days. The duration of symptoms is typically 2 to 5 weeks. 
Monkeypox may be spread from handling bush meat, an animal bite or scratch, body fluids, contaminated objects, or close contact with an infected person. The virus is believed to normally circulate among certain rodents in Africa. Diagnosis can be confirmed by testing a lesion for the virus's DNA. The disease can appear similar to chickenpox.
The smallpox vaccine is believed to prevent infection. Cidofovir may be useful as treatment. The risk of death in those infected is up to 10%.
The disease mostly occurs in Central and West Africa. It was first identified in 1958 among laboratory monkeys. The first cases in humans were found in 1970 in the Democratic Republic of the Congo. An outbreak that occurred in the United States in 2003 was traced to a pet store where imported Gambian rodents were sold.
Chickenpox
Paracetamol (acetaminophen) but not aspirin may be used to reduce fever. Aspirin use by someone with chickenpox may cause the serious, sometimes fatal disease of the liver and brain, Reye syndrome. People at risk of developing severe complications who have had significant exposure to the virus may be given intra-muscular varicella zoster immune globulin (VZIG), a preparation containing high titres of antibodies to varicella zoster virus, to ward off the disease.
Fujian flu
According to the New York Times: "[P]oultry vaccines, made on the cheap, are not filtered and purified [like human vaccines] to remove bits of bacteria or other viruses. They usually contain whole virus, not just the hemagglutinin spike that attaches to cells. Purification is far more expensive than the work in eggs, Dr. Stöhr said; a modest factory for human vaccine costs $100 million, and no veterinary manufacturer is ready to build one. Also, poultry vaccines are "adjuvated" — boosted — with mineral oil, which induces a strong immune reaction but can cause inflammation and abscesses. Chicken vaccinators who have accidentally jabbed themselves have developed painful swollen fingers or even lost thumbs, doctors said. Effectiveness may also be limited. Chicken vaccines are often only vaguely similar to circulating flu strains — some contain an H5N2 strain isolated in Mexico years ago. 'With a chicken, if you use a vaccine that's only 85 percent related, you'll get protection,' Dr. Cardona said. 'In humans, you can get a single point mutation, and a vaccine that's 99.99 percent related won't protect you.' And they are weaker [than human vaccines]. 'Chickens are smaller and you only need to protect them for six weeks, because that's how long they live till you eat them,' said Dr. John J. Treanor, a vaccine expert at the University of Rochester. Human seasonal flu vaccines contain about 45 micrograms of antigen, while an experimental A(H5N1) vaccine contains 180. Chicken vaccines may contain less than 1 microgram. 'You have to be careful about extrapolating data from poultry to humans,' warned Dr. David E. Swayne, director of the agriculture department's Southeast Poultry Research Laboratory. 'Birds are more closely related to dinosaurs.'" Researchers, led by Nicholas Savill of the University of Edinburgh in Scotland, used mathematical models to simulate the spread of H5N1 and concluded that "at least 95 per cent of birds need to be protected to prevent the virus spreading silently. In practice, it is difficult to protect more than 90 per cent of a flock; protection levels achieved by a vaccine are usually much lower than this."
Roselyn J. Eisenberg
She is also very focused on studying the poxvirus variola, also known as smallpox, and the virus that is used as a vaccine against variola, called vaccina. Her main goal is to understand how this virus enters a cell and also to come up with a subunit vaccine that will expand upon and improve the current vaccine for variola, which can have serious side effects and may not be used on pregnant women or individuals with an impaired immune system. She is directing her focus to the entry protein L1, which she believes is the receptor binding protein for vaccina and will be able to improve limitations of the current vaccine for smallpox.
Smallpox vaccine
Smallpox vaccine, the first successful vaccine to be developed, was introduced by Edward Jenner in 1796. He followed up his observation that milkmaids who had previously caught cowpox did not later catch smallpox by showing that inoculated cowpox protected against inoculated smallpox.
Pigeon pox
Pigeon pox is a viral disease to which pigeons are susceptible. There is a live viral vaccine available (ATCvet code: ). Pigeon pox is caused by "Pigeonpox virus" that is spread by mosquitoes and dirty water but not in droppings.